UniQure N.V. was established as a private limited liability company on January 9, 2012 in accordance with the relevant provisions of the Dutch law. The company is a biotechnology company specializing in gene therapy, dedicated to the development of a single treatment pathway for rare and critically ill patients. Its pipeline includes clinical drug candidates for Huntington's disease, amyotrophic lateral sclerosis associated with SOD 1 mutations, refractory median temporal lobe epilepsy and Fabry disease, reflecting the focus on advancing innovative therapies in the field of gene therapy. 

Expected P&L on Expiry

Key Stats

Pricing Model

About QURE20260417C16